Abstral is a rapidly disintegrating sublingual tablet for management of breakthrough cancer pain  in patients already being treated with opioids. The product contains the pain-relieving substance fentanyl. Abstral allows doses to be customized according to individual requirements, which is essential for achieving optimal pain relief.

Short facts  
Technology Sublingual
Indication Breakthrough cancer pain
Commercial rights

Ex-US and EU, Kyowa Kirin

Partner

Kyowa Kirin

Patent protection US and Europe until September 2019, Japan and Australia until 2024

The product was initially approved for sales in Europe in 2008. Approval and launch in other major territories has followed, and Abstral is currently available in key markets such as Japan, Australia and South-Korea. Globally, the market for Abstral has continued to grow rapidly over the years.